Characteristics of Patients with Crimean-Congo Hemorrhagic Fever in a Recent Outbreak in Turkey and Impact of Oral Ribavirin Therapy

Citations Over TimeTop 10% of 2004 papers

Abstract

We describe the epidemiological, clinical, and laboratory findings and the role of ribavirin therapy for 35 patients who received a diagnosis of Crimean-Congo hemorrhagic fever (CCHF). All patients had immunoglobulin M antibodies and/or PCR results positive for CCHF virus in blood or tissue specimens. Eighty-six percent of the patients were considered to have severe cases of CCHF. The overall case-fatality rate was 2.8%. Eight patients were given ribavirin, and all 8 survived. We suggest using ribavirin to treat patients with CCHF, particularly those with severe cases.

Related Papers

• → The Efficacy of Oral Ribavirin in the Treatment of Crimean-Congo Hemorrhagic Fever in Iran(2003)204 cited
• → Ribavirin is not effective against Crimean–Congo hemorrhagic fever: observations from the Turkish experience(2013)33 cited
• → Is Ribavirin Prophylaxis Effective for Nosocomial Transmission of Crimean-Congo Hemorrhagic Fever?(2014)18 cited
• → Bradycardia in a patient with crimean-congo hemorrhagic fever related to ribavirin treatment(2012)9 cited
• → Do We Really Need Ribavirin in the Treatment of Crimean-Congo Hemorrhagic Fever?(2013)9 cited